La gestione condivisa ospedale-territorio del bambino con malattia drepanocitica

1. Weatherall DJ. Thalassemia as a global health problem: recent progress toward its control in the developing countries. Ann N Y Acad Sci 2010;1202:17-23. 2. Roberts I, de Montalambert M. Sickle cell disease as a paradigm of immigration hematology: new challenges for hematologists in Europe. Haematologica 2007;92 (7):865-71. 3. Modell B, Darlison M. Global epidemiology of haemoglobin disorders and derived service indicators. Bull World Health Organ 2008;86 (6):480-7. 4. European Commission. http://ec.europa. eu/health/rare_diseases/policy/index_en.htm. 5. Russo-Mancuso G, Romeo MA, Guardabasso V, Schilirò G. Survey of sickle cell disease in Italy. Haematologica 1998;83(10):875-81. 6. Russo-Mancuso G, La Spina M, Schilirò G. The changing profile of sickle cell disease in Italy. Eur J Epidemiol 2003;18(9):923-4. 7. Colombatti R, Perrotta S, Samperi P, et al.; Italian Association of Pediatric Hematology- Oncology (AIEOP) Sickle Cell Disease Working Group. Organizing national responses for rare blood disorders: the Italian experience with sickle cell disease in childhood. Orphanet J Rare Dis 2013;8:169. 8. Associazione Italiana di Emato-Oncologia Pediatrica. Linee Guida per la Gestione della Malattia Drepanocitica in età pediatrica (2012). http://www.aieop. 9. Bain BJ. Neonatal/newborn haemoglobinopathy screening in Europe and Africa. J Clin Pathol 2009;62(1):53-6. 10. Po’ C, Colombatti R, Cirigliano A, et al. The management of sickle cell pain in the emergency department: a priority for health systems. Clin J Pain 2013;29(1):60-3. 11. Colombatti R, Montanaro M, Guasti F, et al. Comprehensive care for sickle cell disease immigrant patients: a reproducible model achieving high adherence to minimum standards of care. Pediatr Blood Cancer 2012;59 (7):1275-9. 12. de Montalembert M, Ferster A, Colombatti R, Rees DC, Gulbis B; European Network for Rare and Congenital Anaemias. ENERCA clinical recommendations for disease management and prevention of complications of sickle cell disease in children. Am J Hematol 2011;86(1):72-5. 13. Inusa BPD, Colombatti R. European migration crises: the role of national hemoglobinopathy registries in improving patient access to care. Pediatr Blood Cancer 2017;64(7). 14. Ware RE, de Montalembert M, Tshilolo L, Abboud MR. Sickle cell disease. Lancet 2017; 390(10091):311-23. 15. Menzato F, Colombatti R, Sainati L. Gestione delle principali urgenze della drepanocitosi in età pediatrica. Quaderni acp 2016; 23(2):74-6. 16. Vichinsky E, Hurst D, Earles A, Kleman K, Lubin B. Newborn screening for sickle cell disease: effect on mortality. Pediatrics 1988;81 (6):749-55. 17. Colombatti R, Dalla Pozza LV, Mazzucato M, Sainati L, Pierobon M, Facchin P. Hospitalization of children with sickle cell disease in a region with increasing immigration rates. Haematologica 2008;93(3):463-4. 18. Colombatti R, Samperi P, Menzato F, Russo G, Sainati L. Screening neonatale per la malattia drepanocitica: cosa si fa nel mondo, cosa si fa in Europa, perché in Italia? Quaderni acp 2017;24(5):210-3. 19. Colombatti R, Palazzi G, Masera N, et al; Italian Multicenter Study of Hydroxyurea in Sickle Cell Anemia Investigators. Hydroxyurea prescription, availability and use for children with sickle cell disease in Italy: results of a National Multicenter survey. Pediatr Blood Cancer 2017 Sep 4[Epub ahead of print]. 20. Ballardini E, Tarocco A, Marsella M, et al. Universal neonatal screening for sickle cell disease and other haemoglobinopathies in Ferrara, Italy. Blood Transfus 2013;11(2):245-9. 21. Rolla R, Castagno M, Zaffaroni M, et al. Neonatal screening for sickle cell disease and other hemoglobinopathies in “the changing Europe”. Clin Lab 2014;60(12):2089-93. 22. Venturelli D, Lodi M, Palazzi G, et al. Sickle cell disease in areas of immigration of high-risk populations: a low cost and reproducible method of screening in Northern Italy. Blood Transfus 2014;12(3):346-51. 23. Martella M, Cattaneo L, Viola G, et al. Universal newborn screening for sickle cell disease: preliminary results of the first year of a multicentric Italian pilot project. Abstract E1489 at the 22nd EHA Congress, Madrid 22- 25 June 2017. 24. Gaston MH, Verter JI, Woods G, et al. Prophylaxis with oral penicillin in children with sickle cell anemia. A randomized trial. N Engl J Med 1986;314(25):1593-9. 25. Colombatti R, Perrotta S, Masera N, et al. Lessons learned from the H1N1 pandemic: the need to improve systematic vaccination in sickle cell disease children. A multi center survey in Italy. Vaccine 2011;29(6):1126-8. 26. Price VE, Blanchette VS, Ford-Jones EL. The prevention and management of infections in children with asplenia or hyposplenia. Infect Dis Clin North Am 2007;21(3):697-710. 27. Montanaro M, Colombatti R, Pugliese M, et al. Intellectual function evaluation of first generation immigrant children with sickle cell disease: the role of language and sociodemographic factors. Ital J Pediatr 2013;39:36. 28. Manara R, Talenti G, Rampazzo P, et al. Longitudinal evaluation of cerebral white matter hyperintensities lesion volume in children with sickle cell disease. Br J Haematol 2017; 176(3):485-7. 29. Kwiatkowski JL, Zimmerman RA, Pollock AN, et al. Silent infarcts in young children with sickle cell disease. Br J Haematol 2009;146(3): 300-5. 30. Ohene-Frempong K, Weiner SJ, Sleeper LA, et al. Cerebrovascular accidents in sickle cell disease: rates and risk factors. Blood 1998; 91(1):288-94. 31. Adams RJ, McKie VC, Hsu L, et al. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. N Engl J Med 1998;339(1):5-11. 32. Adams R, Brambilla D; Optimizing Primary Stroke Prevention in Sickle Cell Anemia (STOP 2) Trial Investigators. Discontinuing prophylactic transfusions used to prevent stroke in sickle cell disease. N Engl J Med 2005;353(26):2769-78. 33. Colombatti R, Meneghetti G, Ermani M, Pierobon M, Sainati L. Primary stroke prevention for sickle cell disease in north-east Italy: the role of ethnic issues in establishing a Transcranial Doppler screening program. Ital J Pediatr 2009;35:15. 34. Ware RE, Davis BR, Schultz WH, et al. Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia- TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial. Lancet 2016; 387(10019):661-70. 35. Bernaudin F, Verlhac S, Arnaud C, et al. Long-term treatment follow-up of children with sickle cell disease monitored with abnormal transcranial Doppler velocities. Blood 2016;127(14):1814-22. 36. Di Cataldo A, Astuto M, Rizzo G, Bertuna G, Russo G, Incorpora G. Neurotoxicity during ifosfamide treatment in children. Med Sci Monit 2009;15(1):CS22-5. 37. Steinberg MH, Hsu H, Nagel RL, et al. Gender and haplotype effects upon haematological manifestations of adult sickle cell anemia. Am J Hematol 1995;48(3):175-81. 38. Charache S. Fetal hemoglobin, sickling, and sickle cell disease. Adv Pediatr 1990;37:1-31. 39. Lê PQ, Gulbis B, Dedeken L, et al. Survival among children and adults with sickle cell disease in Belgium: benefit from hydroxyurea treatment. Pediatr Blood Cancer 2015;62(11): 1956-61. 40. Lobo CL, Pinto JF, Nascimento EM, Moura PG, Cardoso GP, Hankins JS. The effect of hydroxcarbamide therapy on survival of children with sickle cell disease. Br J Haematol 2013;161(6):852-60. 41. Adragna NC, Fonseca P, Lauf PK. Hydroxyurea affects cell morphology, cation transport, and red blood cell adhesion in coultured vascular endothelial cells. Blood 1994; 83(2):553-60. 42. Saleh AW, Duits AJ, Gerber A, de Vries C, Hillen HF. Cytokines and soluble adhesion molecules in sickle cell anemia patients during hydroxyurea therapy. Acta Haematol 1998;100(1):26-31. 43. Nahavandi M, Wyche MQ, Perlin E, Tavakkoli F, Castro O. Nitric oxide metabolites in sickle cell anemia patients after oral administration of hydroxyurea. Hematology 2000;5 (4):335-9. 44. Charache S, Terrin ML, Moore RD, et al. Effects of hydroxyurea on the frequency of painful crises in sickle cell anemia. N Engl J Med 1995;332(20):1317-22. 45. Kinney TR, Helms RW, O’Branski EE, et al. Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group. Blood 1999;94(5):1550-4. 46. de Montalembert M, Brousse V, Elie C, Bernaudin F, Shi J, Landais P; French Study Group on Sickle Cell Disease. Long-term hydroxyurea treatment in children with sickle cell disease: tolerance and clinical outcomes. Haematologica 2006;91(1):125-8. 47. Parodi E, Giraudo MT, Davitto M, et al. Reticulocyte parameters: markers of early response to oral treatment in children with severe iron-deficiency anemia. J Pediatr Hematol Oncol 2012;34(6):e249-52. 48. Del Vecchio GC, De Santis A, Giordano P, et al.; AIEOP ITP Study Group. Management of acute childhood idiopathic thrombocytopenic purpura according to AIEOP consensus guidelines: assessment of Italian experience. Acta Haematol 2008;119(1):1-7. 49. Angelucci E, Matthes-Martin S, Baronciani D, et al.; EBMT Inborn Error and EBMT Paediatric Working Parties. Hematopoietic stem cell transplantation in thalassemia major and sickle cell disease: indications and management recommendations from an international expert panel. Haematologica 2014;99(5):811-20. 50. Ribeil JA, Hacein-Bey-Abina S, Payen E, et al. Gene therapy in a patient with sickle cell disease. N Engl J Med 2017;376(9):848-55. 51. Ataga KI, Kutlar A, Kanter J, Liles D, et al. Crizanlizumab for the prevention of pain crises in sickle cell disease. N Engl J Med 2017;376(5):429-39. 52. Heeney MM, Hoppe CC, Abboud MR, et al.; DOVE Investigators. A multinational trial of prasugrel for sickle cell vaso-occlusive events. N Engl J Med 2016;374(7):625-35.